1. Supplementary information

1.1 FMIA assay specifications and thresholds for positivity

Assay specificity and sensitivity were determined by analysing sera (n=402) collected in mid-2019 (negative controls) and sera collected in 2020 from subjects (n=87) with PCR-confirmed COVID-19 14-51 days after symptom onset and no COVID-19 vaccination history (positive controls). The positive control sample material has been previously described¹. Samples collected from April to September 2020 (n=3954) were only analysed for N-IgG, and the samples thereafter were analysed for N-IgG and S-IgG (n=5840).

Samples collected from April 2020 to December 2021 (n=7039) were analysed as duplicates diluted 1:100. The threshold for N-IgG positivity during this period was >6.7 BAU/ml resulting in 100% specificity and 95.8% sensitivity. Samples with >0.9 BAU/ml IgG to receptor binding domain and >1.6 BAU/ml IgG to full-length spike glycoprotein were considered S-IgG positive and the assay specificity and sensitivity were 100%.

Samples collected in 2022 (n=2755) were analysed as duplicates diluted 1:100 and 1:1600. The threshold for N-IgG positivity during this period was >7 BAU/ml resulting in 92.8% specificity and 100% sensitivity. Samples with >3 BAU/ml IgG to receptor binding domain and >2 BAU/ml IgG to full-length spike glycoprotein were considered S-IgG positive, and the assay specificity and sensitivity were 100%.

1.2 Supplementary references

1. Dub, T. *et al.* High secondary attack rate and persistence of SARS-CoV-2 antibodies in household transmission study participants, Finland 2020-2021. *Front. Med.* **9**, 876532 (2022).

1.3 Tables

Survey	Week/year	Sample size total/per district	Invited subjects	Participated subjects	Participation rate	Healthcare district
1	14/2020	750	733	468	64%	HUS
2	15/2020	750	728	451	62%	HUS
3	16/2020	1000/200	989	509	51%	All five
4	17/2020	1000/200	980	469	48%	All five
5	17/2020	1000/200	980	480	49%	All five
6	18/2020	750/150	738	313	42%	All five
7	19/2020	400/80	392	162	41%	All five
8	21/2020	400/80	394	145	37%	All five
9	22/2020	400/80	398	171	43%	All five
10	22/2020	900/500 [§] /80	876	314	36%	All five
11	25/2020	400/80	391	132	34%	All five
12	29/2020	400/80	391	130	33%	All five
13	31/2020	400/80	396	138	35%	All five
14	33/2020	400^{*}	392	113	29%	All five
15	35/2020	400^{*}	390	113	29%	All five
16	37/2020	400^{*}	392	112	29%	All five
17	39/2020	400^{*}	387	113	29%	All five
18	41/2020	400^{*}	392	107	27%	All five
19	43/2020	400^{*}	392	104	27%	All five
20	45/2020	600*#	599	174	29%	All five
21	47/2020	600*#	600	170	28%	All five
22	49/2020	600*#	601	171	28%	All five
23	52/2020	600*#	594	164	28%	All five
24	02/2021	600*#	595	160	27%	All five
25	05/2021	600*#	597	192	32%	All five
26	07/2021	600*#	588	178	30%	All five
27	09/2021	600*#	594	184	31%	All five
28	11/2021	400	382	111	29%	HUS
29	14/2021	600*#	599	181	30%	All five
30	15/2021	400	391	119	30%	HUS
31	17/2021	600*#	601	147	24%	All five
32	19/2021	400	390	101	26%	HUS
33	21/2021	600*#	603	123	20%	All five
34	23/2021	400	385	83	22%	HUS
35	27/2021	400	386	86	22%	HUS
36	41/2021	750	728	153	21%	HUS
37	10/2022	2500	2426	377	16%	HUS
38	17/2022	2500	2424	458	19%	HUS
<u>39</u>	19/2022	4000/1000	3929	731	19%	All excl. HUS
40	40/2022	6500/2500 [§] /1000	6358	1190	19%	All five

Table S1. Description of the random population surveys

HUS= Helsinki and Uusimaa healthcare district *sample size per district adjusted by population # sample size for HUS district doubled § sample size for HUS district

		2020	2021	2022
	January	0	53	1
Q1	February	0	413	0
	March	0	418	168
	April	1460	314	87
Q2	May	1305	319	456
	June	685	215	791
	July	201	43	38
Q3	August	244	83	14
	September	242	3	8
	October	245	13	258
Q4	November	261	132	879
	December	382	10	53

Table S2. The number of participants per year and month.

Table S3. Study population compared to Uusimaa region and Finland's 18-85-year-old population structure at the end of 2021.

		Study population n=9794	Uusimaa, Finland, 18-85-year-olds (n=1.35 million)	Whole Finland, 18-85-year-olds (n=4.36 million)
	18-29	11%	19%	18 %
1 22	30-44	25%	29%	25 %
Age	45-64	44%	32%	32 %
	65-85	19% ^a	21%	26 %
Sou	Female	61%	51%	50 %
Sex	Male	39%	49%	50 %
Native language	Finnish or Swedish	97%	85%	91 %
00	Other	3%	15%	9 %
Reside in Uusimaa		54%	100%	31%
Vaccinated for COVID-19 ^b		96% ^d	88%	88%
Registered COVID-19 cases ^c		2518 (26%) ^e	457 528 (34%)	1 219 008 (28%)

^a 65-70-year-olds in 2021-2021 and 65-85-year-olds in 2022.

^b Have received at least one COVID-19 vaccine dose before 15th of December 2021, i.e. would have developed vaccine-mediated immunity by 2022.

^c January 1st 2020 to December 31st 2022.

^d Vaccinated before or after sample collection.

^e Case registered before or after sample collection.

		Number of partic	ipants per health	care district, %	of the quartile's s	amples
Year	Quartile	Helsinki and Uusimaa (HUS)	Pirkanmaa	Northern Ostrobothnia	Northern Savonia	Southwest Finland
	Q2, n=3450	46% (n=1603)	15% (n=517)	12% (n=420)	14% (n=481)	12% (n=429)
2020	Q3, n=687	35% (n=242)	20% (n=135)	16% (n=107)	13% (n=88)	17% (n=115)
	Q4, n=888	65% (n=580)	13% (n=114)	7% (n=63)	7% (n=62)	8% (n=69)
	Q1, n=884	70% (n=618)	11% (n=101)	7% (n=62)	4% (n=37)	7% (n=66)
2021	Q2, n=847	83% (n=705)	6% (n=50)	5% (n=44)	3% (n=22)	3% (n=26)
2021	Q3, n=129	96% (n=124)	3% (n=4)	1% (n=1)	0% (n=0)	0% (n=0)
-	Q4, n=155	100% (n=155)	0% (n=0)	0% (n=0)	0% (n=0)	0% (n=0)
	Q1, n=169	100% (n=169)	0% (n=0)	0% (n=0)	0% (n=0)	0% (n=0)
2022	Q2, n=1335	48% (n=645)	13% (n=179)	11% (n=152)	14% (n=193)	12% (n=166)
2022	Q3, n=60	33% (n=20)	20% (n=12)	5% (n=3)	15% (n=9)	27% (n=16)
	Q4, n=1190	38% (n=451)	16% (n=191)	16% (n=188)	17% (n=202)	13% (n=158)
To	tal, n=9794	54% (n=5312)	13% (n=1303)	11% (n=1040)	11% (n=1094)	11% (n=1045)

Table S4. The number of serological samples collected in Finland's different healthcare districts per year quartile.

Year	Quartile	Analysed samples, n	Age	N-IgG positives %, (n)	S-IgG positives %, (n)
2020			18-29	0.8% (4/523)	NA (0/0)
	Q2	N-IgG:3450	30-44	2.3% (23/1005)	NA (0/0)
	Q2	S-IgG:0	45-64	2.2% (35/1562)	NA (0/0)
			65-70	3.1% (11/360)	NA (0/0)
			18-29	4.5% (3/66)	0.0% (0/10)
	Q3	N-IgG:687	30-44	2.9% (6/204)	4.8% (3/62)
2020	Q 5	S-IgG:183	45-64	2.2% (7/317)	2.3% (2/88)
			65-70	5.0% (5/100)	0.0% (0/23)
		N-IgG:888 S-IgG:888	18-29	6.0% (7/117)	3.4% (4/117)
	Q4		30-44	2.2% (6/269)	0.7% (2/269)
	C .		45-64	2.8% (11/390)	1.5% (6/390)
			65-70	0.0% (0/112)	0.0% (0/112)
		N-IgG:884 S-IgG:884	18-29	2.7% (3/112)	4.5% (5/112)
	Q1		30-44	2.4% (6/249)	5.2% (13/249)
	×-		45-64	3.6% (15/419)	6.9% (29/419)
			65-70	1.9% (2/104)	4.8% (5/104)
		N-IgG:847 S-IgG:847	18-29	4.7% (6/127)	13.4% (17/127)
	Q2		30-44	7.3% (17/232)	27.6% (64/232)
	X -		45-64	4.8% (19/399)	51.1% (204/399)
2021			65-70	3.4% (3/89)	74.2% (66/89)
2021		N-IgG:129 S-IgG:129	18-29	0.0% (0/10)	70.0% (7/10)
	Q3		30-44	6.3% (3/48)	77.1% (37/48)
	Q 5		45-64	3.6% (2/55)	90.9% (50/55)
	-		65-70	0.0% (0/16)	93.8% (15/16)
			18-29	7.1% (1/14)	92.9% (13/14)
	Q4	N-IgG:155	30-44	0.0% (0/41)	82.9% (34/41)
		S-IgG:155	45-64	12.8% (10/78)	89.7% (70/78)
			65-70	4.5% (1/22)	100.0% (22/22)
		N-IgG:169 S-IgG:169	18-29	33.3% (3/9)	100.0% (9/9)
	Q1		30-44	41.2% (14/34)	100.0% (34/34)
			45-64	30.4% (21/69)	100.0% (69/69)
			65-85	19.3% (11/57)	100.0% (57/57)
	Q2	N-IgG:1335 S-IgG:1335	18-29	55.4% (41/74)	95.9% (71/74)
			30-44	44.9% (96/214)	95.3% (204/214)
	×-		45-64	35.6% (195/548)	98.2% (538/548)
2022			65-85	27.9% (139/499)	99.6% (497/499)
	Q3	N-IgG:60 S-IgG:60	18-29	100.0% (4/4)	100.0% (4/4)
			30-44	64.3% (9/14)	92.9% (13/14)
			45-64	38.7% (12/31)	100.0% (31/31)
			65-85	36.4% (4/11)	100.0% (11/11)
	Q4		18-29	71.2% (37/52)	98.1% (51/52)
		N-IgG:1190 S-IgG:1190	30-44	55.8% (96/172)	97.7% (168/172)
			45-64	53.6% (241/450)	98.9% (445/450)
			65-85	39.7% (205/516)	99.2% (512/516)

Table S5. N-IgG and S-IgG seropositivity by year quartile and age group.